NCT02846987进行中（未招募）2 期
Phase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated Liposarcoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- progression-free
研究概览
简要总结
The purpose of this study is to test any good and bad effects of the study drug called Abemaciclib. Abemaciclib could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drug will delay the growth of the cancer or shrink the cancer by at least one quarter compared to its present size. Abemaciclib is not FDA approved and has not been tested in liposarcoma, but it has shrunk tumors in patients with breast cancer, lymphoma, and lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A diagnosis of dedifferentiated liposarcoma confirmed at MSKCC.
- •Metastatic and/or locally advanced or locally recurrent disease that is not surgically resectable.
- •All patients must have measurable disease as defined by RECIST 1.
- •Patients must also have evidence of disease progression by RECIST 1.1 within 6 months of first dose of study drug.
- •Any number of prior therapies (including none) is permitted. The last dose of systemic therapy (include targeted therapies) must have been given at least 2 4 weeks prior to initiation of therapy. Patients receiving BCNU or mitomycin C must have received their last dose of such therapy at least 6 weeks prior to initiation of therapy.
- •Patients with brain metastasis that have been treated with definitive surgery or radiation and have been clinically stable for 3 months are eligible.
- •Age ≥ 18 years.
- •ECOG performance status 0 or 1
- •Adequate organ and marrow function as defined below (ULN indicates institutional upper limit of normal):
- •Absolute neutrophil count ≥ 1.510^9/L
- •Hemoglobin ≥ 8.0 g/dL
- •WBC ≥ 3.0 x 10^9/L
- •Platelets ≥ 100 x 10^9/L
- •Total bilirubin ≤ 1.5 x ULN except for patients with known Gilbert syndrome
- •AST(SGOT)/ALT(SGPT) ≤ 3 x institutional ULN
- •Creatinine ≤ 1.5 x ULN or Creatinine Clearance > 50 mL/min (calculated by Cockcroft-Gault method)
- •Patients must not have current evidence of another malignancy that requires treatment.
- •Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence). Women must not breast feed while on study.
- •Ability to understand and the willingness to sign a written informed consent document.
- •Ability to swallow capsules
排除标准
- •Patients who have not recovered from adverse events of prior therapy to ≤ NCI CTCAEv4.0 Grade
- •Patients receiving any other investigational agents.
- •Patients who have received prior treatment with a selective CDK4 inhibitor
- •Uncontrolled intercurrent illness including, but not limited to, known ongoing or active infection, including HIV, active hepatitis B or C, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (specifically, atrial fibrillation or ventricular dysrhythmias except ventricular premature contractions), or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant women and women who are breast-feeding.
研究组 & 干预措施
Abemaciclib (LY2835219)
Experimental
Patients will be treated with abemaciclib 200 mg bid.
干预措施: Abemaciclib (Drug)
结局指标
主要结局
progression-free
时间窗: 12 weeks
Progression includes both disease progression (as defined by RECIST 1.1) and death from any cause.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung CancerNon-Small Cell Lung Cancer Stage IVNCT02450539Eli Lilly and Company159
进行中（未招募）
2 期
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain TumorsBrain TumorNCT03220646Memorial Sloan Kettering Cancer Center64
已完成
2 期
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the BrainBreast CancerMelanomaNon-small Cell Lung CancerBrain MetastasesNCT02308020Eli Lilly and Company162
终止
2 期
Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate CancerProstate CancerNCT04298983University of Alabama at Birmingham9
终止
1 期
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial TreatmentProstatic NeoplasmsNCT05999968Eli Lilly and Company10